Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B?

Aliment Pharmacol Ther. 2022 Apr;55(8):1042-1043. doi: 10.1111/apt.16854.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Hepatitis B* / drug therapy
  • Humans
  • Tenofovir

Substances

  • Tenofovir